Madeleine C. Laupheimer

I'll research this attorney's professional background before drafting.

Let me verify the tracked cases and the Moderna/Pfizer matter.

One more check on the SoftView declaratory judgment case and her PTAB appearances.

Madeleine C. Laupheimer — Patent Litigation Practice Summary

Specialty / focus. Ms. Laupheimer's practice is intellectual property litigation before federal district courts, the Federal Circuit, and the Patent Trial and Appeal Board, with a documented emphasis on life sciences and pharmaceutical patents. She holds a B.A. in chemistry (Swarthmore) and worked as an associate technologist in an advanced battery group before law school, and her largest publicly documented matters are mRNA/lipid-nanoparticle vaccine and small-molecule pharmaceutical disputes (Moderna; Bristol-Myers Squibb/Pfizer's Eliquis Hatch-Waxman litigation). Her tracked case list also includes consumer-electronics/software-adjacent subject matter through the SoftView mobile-web-content patent proceedings, where she represented Motorola Mobility on appeal. Her practice page describes her IP litigation work generally rather than limiting it to a single technology field.

Side preference. On the three tracked appearances she is defense-side twice and plaintiff-side once, which is consistent with a defense-leaning practice. The broader record shows she works both sides: she appeared for Moderna as plaintiff in ModernaTX, Inc. v. Pfizer Inc. (D. Mass. No. 1:22-cv-11378) and for appellees Apple/Motorola defending SoftView's patent claims, and she was part of the WilmerHale trial team representing BMS and Pfizer as plaintiffs in the Eliquis Hatch-Waxman case. There is no indication of NPE/PAE-side prosecution work.

Firm context. She has been at Wilmer Cutler Pickering Hale and Dorr LLP (WilmerHale), Boston office, appearing in the docket under both the full firm name and the "WilmerHale" short name. Before joining the firm she clerked for Judge Richard G. Taranto of the U.S. Court of Appeals for the Federal Circuit (2016–2017) and Judge F. Dennis Saylor IV of the U.S. District Court for the District of Massachusetts (2017–2018).

Notable matters / outcomes. (1) SoftView LLC v. Apple Inc. & Motorola Mobility LLC, Fed. Cir. Nos. 2023-1005/-1007 (decided July 26, 2024): the court upheld the validity of 37 C.F.R. § 42.73(d)(3)(i) but held it does not apply to previously issued claims, vacating that portion of the PTAB's estoppel-based invalidity ruling while affirming as to amended claims—a split outcome for her appellee clients; a related appeal (Nos. 2023-1006/-1008) was affirmed by nonprecedential judgment on June 6, 2024. (2) ModernaTX, Inc. v. Pfizer Inc. / BioNTech (D. Mass.), the U.S. leg of the global COVID-19 vaccine patent dispute, in which she was Moderna's counsel of record; the parallel PTAB proceedings resulted in a March 5, 2025 ruling invalidating claims of two Moderna patents (IPR2023-01358/-01359), and the district case was stayed pending the IPRs. (3) The Eliquis Hatch-Waxman litigation (D. Del.), where the WilmerHale team obtained an August 5, 2020 bench-trial decision finding infringement by the remaining generic defendants on patents expiring in 2026 and 2031, following settlements with numerous other defendants. One tracked entry in the source data is an untitled defendant-side case and cannot be identified from the available record.

PTAB / IPR experience. Yes—she appears in PTAB-adjacent matters, including the Federal Circuit appeal from IPR2019-00554 (ModernaTX v. Arbutus Biopharma, brief filed February 2021) and the SoftView inter partes reexamination litigation and IPR-driven estoppel appeals. Her firm biography expressly states her practice includes PTAB litigation, though the public record does not show her as first-chair on a large volume of IPR petitions.

Bar / education. J.D., Stanford Law School (2016); B.A., Chemistry, Swarthmore College (2010); admitted in Massachusetts (Bar No. 696647) and registered with the U.S. Patent and Trademark Office; recognized in Best Lawyers: Ones to Watch for IP litigation (2024–2026) and appellate practice (2026).

Note: some sources retrieved (letters in the Moderna/Pfizer docket, recent PTAB filings, and a separate D. Del. matter involving Scale Biosciences/Parse Biosciences) indicate ongoing matters not fully reflected in the tracked case list; the SoftView docket entry listing her on the Federal Circuit parties page is the most reliable confirmation of her appellate role.